SEATTLE, WA--(Marketwired - Sep 6, 2013) - Atossa Genetics, Inc. (
The ForeCYTE Breast Health Test, developed and marketed by Atossa's subsidiary, The National Reference Laboratory for Breast Health, detects reversible precancerous conditions in the breast up to eight years before they become cancer. The test uses Atossa's hand-held, FDA Class II medical device that is quick, painless, and non-invasive and can be administered during an OB/GYN office visit. Unlike mammograms, which are commonly recommended for women starting at age 40 to 50, the ForeCYTE Breast Health Test is more age agnostic, uses no radiation and does not require invasive biopsy needles or surgical incisions. To view a video about the ForeCYTE Test, click here: https://vimeo.com/62365818.
"Our ForeCYTE Breast Health Test provides vital early detection of precancerous abnormalities that can lead to breast cancer over an approximately 8-year time frame," said Chris Destro, Vice President of Atossa. "By identifying women with precancerous abnormalities and empowering them with useful information, we can help women and their doctors to take important steps to reverse the condition through lifestyle changes and/or therapeutic intervention and thereby potentially prevent breast cancer and save lives. We look forward to presenting ForeCYTE's value at the Breast Cancer Symposium in San Francisco."
Atossa's ForeCYTE Breast Health Test is available through physicians nationwide.
About the San Francisco Breast Cancer Symposium
Now in its 7th year, the Breast Cancer Symposium brings together medical and radiation oncologists as well as surgeons to focus on understanding and incorporating the latest research from each subspecialty, in order to strengthen collaborative treatment approaches and to enhance patient care.
About Atossa Genetics, Inc.
Atossa, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, the NRLBH, patented, laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography.
The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.